FDA Guides Faster Path for Generic Drug Approvals
Published Date: 6/16/2025
Notice
Summary
The FDA just released new rules to help generic drug makers send important info about their factories before submitting priority drug applications. This speeds up reviews and helps the FDA set clear goals for fast-tracking these drugs. If you’re in the generic drug business, get ready to share your facility details early to keep things moving smoothly and meet new deadlines tied to the latest fee program.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Send Factory Details Before Priority ANDAs
The FDA's final guidance explains what facility information generic drug makers must send in a pre-submission facility correspondence (PFC) before filing a prioritized Abbreviated New Drug Application (ANDA). The guidance explains how FDA will use that facility information to set a review goal for a priority ANDA.
Guidance Implements GDUFA III Enhancement
The guidance incorporates a program enhancement agreed between FDA and industry as part of the Generic Drug User Fee Amendments (GDUFA) reauthorization and described in the GDUFA III commitment letter for Fiscal Years 2023-2027. The document finalizes the draft guidance that was issued on December 5, 2022.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-10921 — Government-Owned Inventions; Availability for Licensing
The U.S. Government owns some cool inventions and is ready to license them out so companies can bring them to market faster. This means businesses can grab rights to use these inventions, including some with international patent protection. If you’re a company looking to innovate, now’s the time to check out these opportunities and get in on the action!
Next: 2025-10923 — Applications for Membership to the American Fisheries Advisory Committee
The Secretary of Commerce is looking for 7 new members to join the American Fisheries Advisory Committee, which helps guide fishing policies. If you love fish and want to make a difference, now’s your chance! Members will serve for three years, so get ready to dive into some important work soon.